Literature DB >> 6365352

Effect of propranolol in postinfarction patients with mechanical or electrical complications.

C D Furberg, C M Hawkins, E Lichstein.   

Abstract

In "post hoc" subgroup analyses, a simple classification system for patients, based on the presence or absence of findings indicative of electrical and/or mechanical complications early during short-term hospitalization, was applied to the data from the Beta-Blocker Heart Attack Trial (BHAT). In the largest subgroup of BHAT patients who had no reported complications, the 25 month mortality was low and the observed benefit of propranolol therapy small. Patients with electrical complications only had intermediate mortality and a pronounced effect of treatment was observed. Those with mechanical complications had the highest mortality and experienced an intermediate relative benefit of beta-blocker treatment. They also reported the most adverse effects. Post hoc analyses should always be interpreted cautiously. It is important to determine whether these findings are present in other completed beta-blocker trials. On the basis of these analyses alone it is suggested that the present practice of prescribing beta-blockers in postinfarction patients should not be altered.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6365352     DOI: 10.1161/01.cir.69.4.761

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

1.  beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study.

Authors:  K S Spargias; A S Hall; D C Greenwood; S G Ball
Journal:  Heart       Date:  1999-01       Impact factor: 5.994

Review 2.  Therapy of idiopathic dilated cardiomyopathy with chronic beta-adrenergic blockade.

Authors:  E M Gilbert; J B O'Connell; M R Bristow
Journal:  Heart Vessels Suppl       Date:  1991

Review 3.  Applying the results of large clinical trials in the management of acute myocardial infarction.

Authors:  J P Sweeney; G G Schwartz
Journal:  West J Med       Date:  1996-03

Review 4.  Drug treatment of heart failure.

Authors:  C T Dollery; L Corr
Journal:  Br Heart J       Date:  1985-09

5.  Beta blockers, lipids, and coronary atherosclerosis.

Authors:  A Ramani; S Nayak; G N Kundaje; A R Aroor
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-30

Review 6.  Beta-adrenoceptor blockers. An update on their role in acute myocardial infarction.

Authors:  R M Norris
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

7.  Recent advances in drug therapy for coronary artery disease.

Authors:  D D Waters
Journal:  Can Med Assoc J       Date:  1985-03-15       Impact factor: 8.262

Review 8.  Treatment for survivors of acute myocardial infarction: what have we learned from large intervention trials?

Authors:  D G Julian
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

9.  Cardiac remodelling.

Authors:  L B Tan; A S Hall
Journal:  Br Heart J       Date:  1994-10

Review 10.  Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.

Authors:  D Wiest
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.